These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 33091527)

  • 1. Ocular barriers to retinal delivery of intravitreal liposomes: Impact of vitreoretinal interface.
    Tavakoli S; Peynshaert K; Lajunen T; Devoldere J; Del Amo EM; Ruponen M; De Smedt SC; Remaut K; Urtti A
    J Control Release; 2020 Dec; 328():952-961. PubMed ID: 33091527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward smart design of retinal drug carriers: a novel bovine retinal explant model to study the barrier role of the vitreoretinal interface.
    Peynshaert K; Devoldere J; Forster V; Picaud S; Vanhove C; De Smedt SC; Remaut K
    Drug Deliv; 2017 Nov; 24(1):1384-1394. PubMed ID: 28925755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrasound-mediated nanoparticle delivery across ex vivo bovine retina after intravitreal injection.
    Huang D; Chen YS; Thakur SS; Rupenthal ID
    Eur J Pharm Biopharm; 2017 Oct; 119():125-136. PubMed ID: 28602870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ICG-mediated photodisruption of the inner limiting membrane enhances retinal drug delivery.
    Peynshaert K; Vanluchene H; De Clerck K; Minnaert AK; Verhoeven M; Gouspillou N; Bostan N; Hisatomi T; Accou G; Sauvage F; Braeckmans K; De Smedt S; Remaut K
    J Control Release; 2022 Sep; 349():315-326. PubMed ID: 35803327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The obstacle course to the inner retina: Hyaluronic acid-coated lipoplexes cross the vitreous but fail to overcome the inner limiting membrane.
    Devoldere J; Wels M; Peynshaert K; Dewitte H; De Smedt SC; Remaut K
    Eur J Pharm Biopharm; 2019 Aug; 141():161-171. PubMed ID: 31150809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanical Disruption of the Inner Limiting Membrane In Vivo Enhances Targeting to the Inner Retina.
    Do JL; Pedroarena-Leal N; Louie M; Avila Garcia P; Alnihmy A; Patel A; Weinreb RN; Wahlin KJ; La Torre Vila A; Welsbie DS
    Invest Ophthalmol Vis Sci; 2023 Dec; 64(15):25. PubMed ID: 38117244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyaluronic acid coating of gold nanoparticles for intraocular drug delivery: Evaluation of the surface properties and effect on their distribution.
    Apaolaza PS; Busch M; Asin-Prieto E; Peynshaert K; Rathod R; Remaut K; Dünker N; Göpferich A
    Exp Eye Res; 2020 Sep; 198():108151. PubMed ID: 32721426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of hyaluronic acid-binding to lipoplexes on intravitreal drug delivery for retinal gene therapy.
    Martens TF; Peynshaert K; Nascimento TL; Fattal E; Karlstetter M; Langmann T; Picaud S; Demeester J; De Smedt SC; Remaut K; Braeckmans K
    Eur J Pharm Sci; 2017 May; 103():27-35. PubMed ID: 28223236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigating Ex Vivo Animal Models to Test the Performance of Intravitreal Liposomal Drug Delivery Systems.
    Christensen G; Barut L; Urimi D; Schipper N; Paquet-Durand F
    Pharmaceutics; 2021 Jul; 13(7):. PubMed ID: 34371707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-viral delivery of chemically modified mRNA to the retina: Subretinal versus intravitreal administration.
    Devoldere J; Peynshaert K; Dewitte H; Vanhove C; De Groef L; Moons L; Özcan SY; Dalkara D; De Smedt SC; Remaut K
    J Control Release; 2019 Aug; 307():315-330. PubMed ID: 31265881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases.
    Bisht R; Mandal A; Jaiswal JK; Rupenthal ID
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2018 Mar; 10(2):. PubMed ID: 28425224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomes and nanotechnology in drug development: focus on ocular targets.
    Honda M; Asai T; Oku N; Araki Y; Tanaka M; Ebihara N
    Int J Nanomedicine; 2013; 8():495-503. PubMed ID: 23439842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal drug delivery in retinal disease: are we out of our depth?
    Thakur SS; Barnett NL; Donaldson MJ; Parekh HS
    Expert Opin Drug Deliv; 2014 Oct; 11(10):1575-90. PubMed ID: 24931577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comment on "Topical Delivery of Avastin to the Posterior Segment of the Eye In Vivo Using Annexin A5-Associated Liposomes": Topical Liposomal Bevacizumab Results in Negligible Retinal Concentrations.
    Urtti A
    Small; 2019 Apr; 15(15):e1805199. PubMed ID: 30977598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging, quantitation and kinetic modelling of intravitreal nanomaterials.
    Sadeghi A; Ruponen M; Puranen J; Cao S; Ridolfo R; Tavakoli S; Toropainen E; Lajunen T; Ranta VP; van Hest J; Urtti A
    Int J Pharm; 2022 Jun; 621():121800. PubMed ID: 35533923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trans-Ocular Electric Current In Vivo Enhances AAV-Mediated Retinal Transduction in Large Animal Eye After Intravitreal Vector Administration.
    Song H; Zeng Y; Sardar Pasha SPB; Bush RA; Vijayasarathy C; Qian H; Wei L; Wiley HE; Wu Z; Sieving PA
    Transl Vis Sci Technol; 2020 Jun; 9(7):28. PubMed ID: 32844051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coating nanocarriers with hyaluronic acid facilitates intravitreal drug delivery for retinal gene therapy.
    Martens TF; Remaut K; Deschout H; Engbersen JF; Hennink WE; van Steenbergen MJ; Demeester J; De Smedt SC; Braeckmans K
    J Control Release; 2015 Mar; 202():83-92. PubMed ID: 25634806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanotherapy for posterior eye diseases.
    Kaur IP; Kakkar S
    J Control Release; 2014 Nov; 193():100-12. PubMed ID: 24862316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular Pharmacokinetics of Therapeutic Antibodies Given by Intravitreal Injection: Estimation of Retinal Permeabilities Using a 3-Compartment Semi-Mechanistic Model.
    Hutton-Smith LA; Gaffney EA; Byrne HM; Maini PK; Gadkar K; Mazer NA
    Mol Pharm; 2017 Aug; 14(8):2690-2696. PubMed ID: 28631484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly(ortho ester) nanoparticles targeted for chronic intraocular diseases: ocular safety and localization after intravitreal injection.
    Li H; Palamoor M; Jablonski MM
    Nanotoxicology; 2016 Oct; 10(8):1152-9. PubMed ID: 27108911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.